Immunological Aspects of Malignant Gliomas
/in Dendritic Cells, Glioblastoma, International Publications /von 2016-07-01 / Can J Neurol Sci 2016 Jul;43(4):494-502NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients
/in Dendritic Cells, International Publications, Malignant Lymphoma /von 2016-06-29 / J. Immunol. 2016 08;197(3):795-806HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer
/in Dendritic Cells, International Publications /von 2016-06-27 / Cell. Mol. Immunol. 2018 02;15(2):135-145Dendritic cell vaccination in melanoma patients: From promising results to future perspectives
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-06-20 / Hum Vaccin Immunother 2016 10;12(10):2523-2528Anti-tumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro.
/in Breast Cancer, Dendritic Cells, International Publications /von 2016-06-17 / J Clin Oncol 36, 2018 (suppl; abstr e24000)Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-06-17 / Oncoimmunology 2016 Aug;5(8):e1201625Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies
/in Acute Leukemia, Chronic Leukemia, Dendritic Cells, International Publications /von 2016-06-09 / Expert Opin Biol Ther 2016 09;16(9):1113-23Dendritic cells-based vaccine to inhibit triple-negative breast cancer cells proliferation.
/in Breast Cancer, Dendritic Cells, International Publications /von 2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr e12566)Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).
/in Breast Cancer, Dendritic Cells, International Publications /von 2016-06-05 / J Clin Oncol 34, 2016 (suppl; abstr 1086)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de